Oct 21, 2025｜2025
mOS in nsqNSCLC Exceeds Two Years! Henlius Announces Latest Results for Serplulimab at ESMO 2025
On October 21, 2025, Henlius (2696.HK) announced that the latest results of multiple studies in the fields of lung cancer and gastrointestinal tumours for its self-developed innovative anti-PD-1 mAb HANSIZHUANG (serplulimab, Hetronifly® in Europe) were released at the 2025 European Society for Medical Oncology Annual Meeting (ESMO 2025). Among them, the final analysis results of the Phase III clinical study (ASTRUM-002) of serplulimab for first-line treatment of advanced non-squamous non-small cell lung cancer (nsqNSCLC) were selected for the conference's Late-breaking Abstract (LBA) and the overall survival (OS) data was orally presented for the first time. The final analysis results showed that the median overall survival (mOS) for the serplulimab plus chemotherapy group reached 26.8 months, successfully surpassing the two-year mark.
Focusing on high-incidence solid tumours such as lung and gastrointestinal cancers, serplulimab has continuously achieved breakthrough progress. It is the world’s first anti-PD-1 mAb approved for first-line treatment of small cell lung cancer and has been approved in nearly 40 countries and regions, including China, the UK, Germany, Singapore and India, covering nearly half of the global population. In October 2025, the phase 3 clinical trial of HANSIZHUANG for perioperative gastric cancer treatment met its EFS primary endpoint, becoming world-first regimen in gastric cancer that replaces adjuvant chemotherapy with mono-immunotherapy in the perioperative setting, supporting an early New Drug Application (NDA) submission. To date, serplulimab has been approved for the treatment of squamous NSCLC (sqNSCLC), extensive-stage SCLC (ES-SCLC), esophageal squamous cell carcinoma (ESCC), and non-squamous NSCLC (nsqNSCLC). Bridging studies for ES-SCLC are currently underway in the United States and Japan.
Comprehensive coverage for first-line lung cancer treatment, long-term survival exceeding two years for advanced nsqNSCLC
In the field of lung cancer, serplulimab has fully covered the first-line lung cancer treatment. Based on the results of the Phase III clinical study (ASTRUM-002) for serplulimab plus chemotherapy in first-line treatment of advanced nsqNSCLC, serplulimab was approved for this indication in China in December 2024. At the ESMO 2025 conference, the leading principal investigator of ASTRUM-002, Professor Yuankai Shi from Cancer Hospital, Chinese Academy of Medical Sciences, orally presented the final analysis results as of August 7, 2025, formally announcing the key secondary endpoint OS data for the first time, further validating the long-term survival benefits brought by this regimen to patients with advanced nsqNSCLC. Previously, this study had released data (as of June 15, 2023), including results of the primary endpoint PFS, at the WCLC 2025 conference.
The study results confirmed that serplulimab plus chemotherapy can confer significant survival benefits to patients with treatment-naïve, locally advanced or metastatic nsqNSCLC. Its outstanding long-term efficacy and controllable safety provide patients with an alternative first-line treatment option.
Breakthroughs in gastrointestinal tumours to address unmet clinical needs
In the field of gastrointestinal tumours, serplulimab has also achieved critical clinical breakthroughs. In October 2025, the Phase 3 clinical study ASTRUM-006 for perioperative gastric cancer reached the primary study endpoint EFS, becoming the world's first treatment regimen for perioperative gastric cancer to replace adjuvant chemotherapy with mono-immunotherapy in the perioperative setting, potentially reshaping the new standard for perioperative gastric cancer treatment and bringing hope for a cure to early gastric cancer patients. The interim analysis results showed that compared with placebo plus chemotherapy, HANSIZHUANG plus chemotherapy significantly prolonged EFS and achieved a more than threefold higher pathological complete response (pCR) rate compared with the control arm, with a significant reduction in the risk of recurrence. Furthermore, the combination regimen demonstrated a favorable safety profile, with no new safety signals identified. Based on this positive outcome, the IDMC has recommended an early NDA submission.
Additionally, the international multicenter Phase 3 clinical study (ASTRUM-015) of serplulimab combined with bevacizumab and chemotherapy for first-line treatment of metastatic colorectal cancer (mCRC) patients has completed patient enrollment. Several exploratory IIT studies of serplulimab plus chemotherapy for neoadjuvant treatment of locally advanced gastric or gastroesophageal junction adenocarcinoma, mid-low rectal cancer, and first-line treatment of advanced pancreatic cancer when combined with bevacizumab were also updated at this conference.
Specific information on studies of serplulimab at this conference is as follows:
Title: Final Analysis of First-Line Serplulimab Plus Chemotherapy With or Without HLX04 in Advanced Nonsquamous Non-small Cell Lung Cancer: the ASTRUM-002 Phase 3 Study
Study design: This was a three-arm, randomised, double-blind, multicentre, phase 3 study. Patients with locally advanced or metastatic nsqNSCLC without EGFR sensitizing mutations or ALK/ROS1 rearrangements and no prior systemic therapy were randomised 1:1:1 to receive serplulimab + HLX04 + chemotherapy (chemo) (group A), serplulimab + chemo (group B), or chemo (group C). The primary endpoint was the BICR-assessed PFS per RECIST version 1.1. The key secondary endpoint was OS.
Results: Between Nov. 25, 2019 to Jun. 15, 2022, 636 patients were enrolled across 72 hospitals in China and randomised to group A (n=212), B (n=214), or C (n=210), with a median follow-up duration of 48.4 (95% CI 45.9–49.9), 45.4 (95% CI 43.3–49.1), and 45.7 (95% CI 43.6–51.7) months, respectively. Median OS was 23.7 months (95% CI 20.5–27.5), 26.8 months (95% CI 21.2–30.9), and 20.3 months (95% CI 16.2–24.6), in group A, B, and C, respectively. A significant reduction in risk of death for group B compared to C was observed (HR=0.66, 95% CI 0.52–0.83, p=0.0004), while no statistical difference was observed for group A compared to B (HR=1.12, p=0.3628). By the time of the final analysis, 79 (37.6%) patients in group C had crossed over to serplulimab plus HLX04 treatment. Median OS in group C as adjusted by the two-stage model was 14.2 months (95% CI: 11.9–17.0), resulting in an adjusted HR of 0.53 (95% CI: 0.42–0.68, p<0.0001) for group B versus group C. Subgroup analysis of median OS was consistent with that of the primary findings. Median PFS and tumour response continued to be improved for group B compared to group C. Treatment-related adverse events leading to death occurred in 10 (4.7%), 5 (2.3%), and 7 (3.3%) patients, in group A, B, and C, respectively.
Conclusion: The combination of serplulimab to chemo significantly prolonged OS and continued to confer significant PFS and clinical benefits compared to chemo alone, making it a promising first-line treatment option for patients with locally advanced or metastatic nsqNSCLC. The addition of HLX04 to serplulimab and chemo did not lead to a further improvement. Both investigated treatment regimens had manageable safety profiles.
Title: Surgery versus radiotherapy after induction therapy with serplulimab combined with chemotherapy for unresectable stage IIIB-IIIC non-small cell lung cancer: a randomized controlled, open-label, phase 2 trial
Results: One hundred patients were enrolled, and the median follow-up time was 20.3 months by the data cutoff date (April 28, 2025). Sixty-six and 34 patients were diagnosed with stage IIIB and IIIC disease, respectively. Fifty patients were randomly assigned to either the surgery group (n = 23) or the radiotherapy group (n = 27). The percentage of squamous carcinomas, adenocarcinomas, and NSCLC not otherwise specified were 70.0%, 16.0%, and 14.0%, respectively. In the entire enrolled patients, ORR was 75.0%. In total, 33 patients received surgery (all achieving R0 resection) after 1-4 cycles of induction chemoimmunotherapy, and the MPR rate was 66.7% (22/33). The median EFS and OS for the entire study cohort were 17.7 months and not reached, respectively. Among randomized patients, the hazard ratio (HR) for surgery versus radiotherapy in EFS in the intention-to-treat and per-protocol populations were 0.35 (95% CI: 0.13-0.91, P = 0.025) and 0.21 (95% CI: 0.07-0.59, P = 0.003), respectively. While, no significant difference in OS was observed. SAE and grade 3-5 treatment-related adverse event rates in induction therapy phase were 12.0% and 58.0%, respectively.
Conclusion: Induction therapy with serplulimab and chemotherapy converted half of the patients with unresectable stage IIIB–IIIC NSCLC to resectable disease and demonstrated promising survival outcomes. Among patients whose disease was converted to resectable, those who underwent surgery showed a trend toward improved event-free survival (EFS) compared with those who received radiotherapy. Induction therapy with serplulimab and chemotherapy, followed by either surgery or radiotherapy, revealed no new safety signals.
Title: Total neoadjuvant chemotherapy plus PD-1 antibody in locally advanced gastric or gastro-esophageal junction adenocarcinoma: A proof-of-concept, phase 2 trial
Results: Between Mar 2023 and Jan 2024, 30 patients were enrolled. All patients received at least one cycle of assigned neoadjuvant treatment, and the median cycles were seven (IQR: 6-8). Among the 25 patients who underwent surgery, eight patients achieved pCR. A total of 3 patients who completed total neoadjuvant serplulimab and chemotherapy and underwent at least 12 months of follow-up achieved a cCR. Therefore, the pCR/12m-cCR rate was 36.7% (11/30, 95% CI: 19.9%-56.1%).
Conclusion: Total neoadjuvant chemotherapy plus PD-1 antibody might be a promising option for patients with locally advanced gastric or GEJ cancer.
Title: Serplulimab Combined with CapeOX and Celecoxib as Neoadjuvant Therapy for Proficient Mismatch Repair Locally Advanced Mid-to-Low Rectal Cancer (SCAR)
Results: As of Jan 2025, 22 patients were enrolled, with a median age of 60.5 years, 86.4% being male. 16 achieved PR or CR before surgery, with ORR of 72.7% (16/22; 95% CI: 49.8-89.3%). 18 (81.8%) patients have received radical surgery. R0 resection rate was 100%. After pathological evaluation, 4 patients achieved PCR(22.2%).No new safety signal was discovered during perioperative period.ScRNA-seq analysis revealed increased CD8+ T cell levels in PR and CR patients
Conclusion: The combination of serplulimab, CapeOX, and celecoxib as neoadjuvant therapy for locally advanced mid-to-low rectal cancer demonstrated primary efficacy and safety.
Title: First-line Serplulimab and Bevacizumab Combined with Nab-Paclitaxel/Gemcitabine Followed by mFOLFOX in Advanced Pancreatic Cancer: A Phase II Trial
Results: Among the 37 patients analyzed, the average age was 62 years. Patients had an adequate nutritional and performance status, with a mean BMI of 21.6 kg/m2. Distant organ metastases were present in 34 patients (91.9%), with the liver being the most common site (n=26, 70.3%).The confirmed ORR was 67.6% (95% CI, 49.5-82.6).1 patient had a complete response (CR).The median PFS was 10.5 months (95% CI, 9.7-not reached). 6-month PFS rate of 80.0% (95% CI, 65.5-97.7). The OS remains immature.The median duration of response (DOR) was 9.3 months, The median time to response (TTR) was 1.5 months. grade ≥3 TRAEs occurring in 46.0% of patients.Hematologic toxicities were the most common treatment-emergent adverse events. No fatal AEs were observed.
Conclusion: First-line serplulimab and bevacizumab biosimilar combined with nab-P/Gem-mFOLFOX demonstrates clinical feasibility and promising preliminary outcomes in advanced PC. Further follow-up is required to confirm the survival benefits, and following analyses are needed to explore the mechanisms underlying the efficacy of this novel regimen.
Back
Privacy Policy
Cookies Policy
Accessibility
Terms of Use
Privacy Policy
Introduction
Shanghai Henlius Biotech, Inc., and, where applicable, its affiliates and subsidiaries (collectively, “we” , “us” or “our”) attach great importance to the protection of your privacy and personal information. This Privacy Notice (this “Policy”) is formulated in accordance with applicable PRC laws and regulations governing the protection of personal information in the People’s Republic of China (“PRC”).
This Policy applies when: (1) you browse or use our website and other online resources (such as our WeChat official accounts); (2) subscribe to our news or announcements; or (3) contact us through the contact details or other interactive features made available on our website, or otherwise interact with us through our website.. The purpose of this Policy is to explain how and why we process your personal information, the types of personal information involved, applicable retention periods, your rights, and the measures we take to protect personal information. Please read this Policy carefully to ensure that you fully understand its content.
In certain business scenarios, we may provide additional explanations regarding the processing of your personal information through separate agreements, privacy statements, or personal information notices. In the event of any inconsistency, such documents shall prevail. For example, where a recruitment function is provided through a third-party platform or service, the relevant third party privacy policy or notice may also apply.
For the purposes of this Policy, “personal information” refers to all kinds of information related to identified or identifiable natural persons, excluding anonymized information.
We collect, use, store, transfer and otherwise process personal information in strict compliance with applicable PRC laws and regulations of the People’s Republic of China.
Our website may contain links to third party websites for your convenience. We do not control, and are not responsible for, the privacy practices of such third parties. We encourage you to review their privacy policies before using those websites.
If you have any questions or concerns regarding this Policy or our processing of personal information, please contact us using the details provided below.
This Policy will help you understand:
I. How we collect your personal information
II. How we use your personal information
III. How we entrust, share, transfer and publicly disclose your personal information
IV. Cross border transfer of personal information
V. How we store your personal information
VI. Security measures
VII. Your rights
VIII. Personal information of minors
IX. Updates to this Policy
X. How to contact us
I. How do we collect your personal information?
In addition to our employees, we may process personal information of the following persons:
• Visitors and users of our website;
• Healthcare Professionals;
• Investigators of clinical trial institutions and personnel of contract research organizations in clinical trials;
• Subjects of clinical trials and their relatives;
• Consumers/patients and their relatives using our products or services;
• Staff of business partners (including vendors, distributors, partners, etc.); and
• Our applicants.
We may process personal information of website visitors and individuals who contact or interact with us through our website or other online resources. Depending on the relevant page, function, or interaction, separate privacy notices, consents, platform privacy policies, contracts, or other notices may apply.
Based on the context in which you interact with us, we may collect personal information by the following means and on the legal bases permitted by applicable PRC laws and regulations, including your consent, the necessity for entering into or performing a contract, compliance with legal obligations, protection of life, health or property, public health needs, or other circumstances permitted by law:
• Your personal information provided to us voluntarily
When you subscribe to our news or announcements, contact us through the contact details or other interactive features made available on our website, a third-party platform or service linked or referred to on our website, or otherwise communicate with us in relation to our website, we may collect the personal information that you voluntarily provide, such as your name, contact details, organization, and the content of your inquiry or request, depending on the relevant page or function.
• Personal information collected by us independently through our website and other online channels
When you visit our website, most of our services do not require any registration, and you can visit our website without telling us who you are. However, some pages or functions may require you to provide certain personal information. If you choose not provide such information as we request, you may not be able to access certain content or functions or we may not be able to respond to your inquiry, request or subscription. Please refer to the relevant page or notice for further details about the categories of personal information collected in a specific scenario.
• Personal information we collect from vendors or business partners
In the course of our daily business operations, we may collect personal information from our vendors or business partners. We require our vendors and business partners to comply with the requirements of the personal information protection laws and regulations of the PRC and to lawfully provide us with personal information. If you are an employee or representative of one of our vendors or business partners, we may collect personal information such as your name and contact details for the purpose of establishing business contacts and cooperations.
• Personal information we collect from publicly available sources
We may collect personal information of medical and healthcare professionals from such publicy available sources, such as the official websites of medical institutions and the official websites of competent government departments, and process such information within a reasonable scope and for lawful purposes. For example, for the purpose of lawful academic or professional interaction with healthcare professionals, we may collect the name, gender, employer, position, practitioner registration information, academic title, degree, educational background, specialty expertise, and profile information, where such information has been lawfully made public.
Our website may include links, contact details, QR codes, or references to third-party platforms or services. Where you choose to interact with us through such third-party platforms or services, the relevant third party may also process your personal information in accordance with its own privacy policy and applicable law, and we encourage you to review such policy before submitting your information.
II. How do we use your personal information?
We may use your personal information for the following purposes:
• Operating, maintaining and improving our website and other online resource;
• Researching, developing, providing and continuously improving our products and services;
• Conducting and managing daily business;
• Academic interaction with healthcare professionals;
• Responding to your inquiries, requests, or communications sent through our website or the contact details made available on our website;
• Providing subscription services for our news, announcements, or investor-related updates;
• Managing and maintaining our relationship and communications with business contacts who reach us through our website;
• Recruiting and human resource management;
• Internal compliance management，audit，record-keeping; and
• Complying with applicable PRC laws and regulations, for example, monitoring and reporting adverse events for purposes of performing drug quality management responsibilities, providing medical information and dealing with product complaints, etc..
We will process personal information only to the extent necessary for the relevant purpose. Where required by applicable law, we will obtain your consent or separate consent before processing your personal information or sensitive personal information. Where a third-party platform or service is used in connection with a particular function, the relevant third party may process your personal information in accordance with its own privacy policy and applicable law.
III. How do we entrust, share, transfer and publicly disclose your personal information?
1. Entrustment
We may entrust our business partners with the processing of your personal information for the purpose(s) described in this Policy. We will enter into appropriate confidentiality, data processing and security agreements with such entrusted parties and require them to process personal information in accordance with our instructions , this Policy and applicable PRC laws and regulations.
2. Sharing and public disclosure
For the purpose(s) described in this Policy, we will share or publicly disclose your personal information only where permitted by applicable PRC laws and regulations and, where required, after obtaining your consent or separate consent. Such circumstances may include:
• Sharing your personal information among our affiliates and subsidiaries where necessary for legitimate business, management, compliance, or operational purposes;
• Sharing your personal information with vendors or business partners (such as conference service providers, travel service providers, data service providers, banking or insurance institutions, other professional service organizations, to the extent necessary for the relevant purpose); and
• Disclosing your personal information to the extent that it is permitted or required by applicable PRC laws and regulations or for the purpose of assisting with investigations by judicial, regulatory or law enforcement authorities.
• other circumstances permitted by applicable PRC laws and regulations.
If you submit your information through or in connection with a third-party platform or service referred to on our website, the relevant third party may independently process your personal information in accordance with its own privacy policy and applicable law.
3. Transfer
We will not transfer your personal information to any other company, entity or individual unless otherwise permitted by applicable law and, where required, after obtaining your consent. Further, in the event of a merger, acquisition, insolvency, reorganization, division, dissolution, bankruptcy, or similar transaction, we will require the new processor of your personal information to continue to be bound by this Policy or we will require the new processor to obtain your consent again.
IV.How do we provide your personal information across borders?
In principle, personal information that we collect and generate in the course of our operations within the territory of the PRC will be stored within the PRC. In certain circumstances, it may be necessary for us to provide your personal information to recipients outside the PRC in connection with our business operations, website functions, or communications, where permitted by applicable PRC laws and regulations. As required by applicable laws and regulations regarding the protection of personal information, we will provide you with the required notice and obtain your separate consent before providing your personal information across any border, unless otherwise permitted by law. We will use lawful cross-border transfer mechanisms to transfer your personal information oversea and will take necessary measures to ensure that the oversea recipients provide a level of protection required by applicable PRC laws and regulations.
You may obtain more information about cross-border transfers of personal information and oversea recipients through the contact methods referred to in this Policy.
V. How do we store your personal information?
We will retain your personal information for the minimum period necessary to achieve the purposes described in this Policy ,unless a longer retention period is required or permitted by applicable PRC laws and regulations. Upon expiration of the applicable retention period, we will promptly delete or anonymize your personal information in accordance with applicable PRC laws and regulations. Our criteria for determining the period for which personal information shall be retained include:
• Applicable laws, regulations and other relevant requirements;
• The period of time needed for us to provide services, maintain business relations or interact with you; and
• The period of time needed for us to perform relevant agreements or fulfil the purposes described in this Policy.
VI. What security measures do we take to protect your personal information?
In accordance with applicable PRC laws, regulations, and the requirements of relevant national standards, we take reasonable and appropriate security and precautionary measures to protect the personal information we process against unauthorized access, public disclosure, use, modification, destruction or loss of data. However, you are also responsible for taking appropriate measures to protect the security of the devices, systems, and networks you use when accessing our website or communicating with us.
VII. Your rights
In accordance with the requirements of the applicable PRC laws and regulations, you may have the following rights in respect of your personal information:
• To know about and make decisions regarding the processing of your personal information;
• To access or copy your personal information;
• To correct or supplement your personal information;
• To delete your personal information;
• To request for explanation of rules regarding processing of personal information; and
• To change the scope of your consent or revoke your consent , where processing is based on your consent.
If you wish to exercise your rights with respect to personal information, you may contact us through the contact information listed in this Policy and we will respond to any request in accordance with applicable relevant laws and regulations. When you exercise the above rights, we may verify your identity to safeguard the security of your personal information. Subject to applicable PRC laws and regulations, there may be circumstances where we are unable to respond to all or part of your request.
VIII. How do we process the personal information of minors?
For the purposes of this Policy and in accordance with applicable PRC laws and regulations, our products, websites and services are not targeted at minors under the age of 14. Minors under the age of 14 should not provide personal information to us without the consent of a parent or legal guardian.
If a minor's personal information is collected with the consent of a parent or legal guardian, we will process the information only when permitted by law, with the express consent of the parent or legal guardian, or necessary for the protection of the minor. If we discover that we have collected personal information without obtaining verifiable prior consent of a parent or legal guardian, we will seek to delete the data as soon as possible.
IX. Updates of the Policy
We may revise our Privacy Policy from time to time. We will post the updated version on our website and update the “Last Updated” date above or below this Policy.
Last updated: March 30, 2026.
X. How to contact us?
If you have any questions, comments or suggestions concerning this Policy, or any questions or concerns about our processing of your personal information, you may contact us in the following ways:
Address: 11/F, B8 Building, No.188 Yizhou Rd, Xuhui District, Shanghai
Tel.: 021- 33395800
Postal Code: 200233
Email: [email protected]
Cookies Policy
When you visit our website, we may place small data files known as “cookies” on your device. Cookies enable our website to recognize your browser and help us understand how visitors use the site.
Cookies and similar technologies used on this website may collect online identifiers, device information, browser information, IP address, and information about how you interact with the website. In certain circumstances, such information may constitute personal information or may be associated with you under applicable PRC laws and regulations. Information collected through cookies is used for purposes such as ensuring website operation, maintaining security, analyzing traffic and performance, remembering user preferences, and improving website content and user experience.
You may choose to accept or decline cookies by adjusting your browser settings or through any cookie banner or preference center made available on our website, if applicable. Please note that disabling cookies may affect the functionality of certain parts of the website.
For more information about how we process personal information, please refer to our Privacy Notice.
Some cookies may be provided by third parties. Where third-party cookies or similar technologies are used, such third parties may process the relevant information in accordance with their own privacy policies and applicable PRC laws and regulations.
Accessibility
Shanghai Henlius Biotech, Inc. (“Henlius”) is committed to improving the accessibility and user friendliness of its website for all visitors.
We strive to ensure that the content on our website can be accessed and used by individuals with diverse needs, including those who rely on assistive technologies. As our website continues to evolve, we recognize that accessibility is an ongoing effort, and we are continuously working to improve usability and accessibility across our digital platforms.
If you experience difficulty accessing any part of our website, or have suggestions on how we can enhance accessibility, we welcome your feedback. To help us respond effectively, please include the specific webpage address (URL) and a brief description of the issue encountered.
Contact us:
Email: [email protected]
(Please include “Website Accessibility” in the subject line)
Henlius will make reasonable efforts to review accessibility-related feedback and improve the overall online experience for all users. While we strive to improve accessibility, we do not guarantee that every page or feature will be fully accessible to every user in all circumstances.
Terms of Use
This website (http:/) is developed and operated by Shanghai Henlius Biotech, Inc. (“Henlius”). Please read these Terms of Use carefully before accessing or using this website. By accessing, browsing or using this website, you acknowledge that you have read, understood and agreed to be bound by these Terms of Use and applicable PRC laws and regulations.
Henlius reserves the right to modify or update these Terms of Use at any time. Any updated version will be posted on this website with a revised “Last Updated” date. Please review them periodically for updates.
Prohibited Conduct:
You shall not infringe the lawful rights and interests of Henlius or any third party, nor interfere with or attempt to interfere with the normal operation, security, or integrity of this website by any means. Without limitation, you shall not use this website for any unlawful purpose, attempt unauthorized access to any part of the website or related systems, introduce malicious code, scrape or extract website content through automated means, or otherwise interfere with the website’s operation or security features.
Copyright
All content on this website, including but not limited to text, data, logos, graphics, audio, video and other materials, is owned by Henlius or its respective rights holders, unless otherwise stated. Such content is protected by applicable Chinese and international copyright laws. This website and its content may be accessed and used only for lawful, personal, and non-commercial purposes. Without prior written consent, no entity or individual may copy, reproduce, republish, upload, post, transmit, distribute, modify, create derivative works from, mirror, or otherwise use such content for commercial or public purposes.
Disclaimers
To the fullest extent permitted by applicable PRC laws and regulations, Henlius makes no warranties or representations, express or implied, regarding the content of this website, including but not limited to accuracy, completeness, timeliness or suitability for any particular purpose. Henlius does not undertake any obligation to update the content of this website , except as otherwise required by applicable PRC laws and regulations.
You use this website and any information obtained from it at your own risk. To the fullest extent permitted by applicable PRC laws and regulations, Henlius shall not be liable for any loss or damage arising from the use or inability to use this website, including but not limited to system failures, computer viruses or data loss.
Medical Information
Nothing on this website constitutes medical advice, diagnosisor treatment recommendations. Medical decisions should always be made in consultation with qualified healthcare professionals. Any product-related or disease-related information provided on this website is provided for general informational purposes only and should not be construed as medical advice, diagnosis, or treatment recommendations; any product information is subject to the approved prescribing information and applicable local laws and regulations.
Third Party Websites
This website may contain links to third party websites for convenience. Henlius is not responsible for the content, availability, privacy practices, terms or use of such third-party websites. Access to third party websites is at your own risk.
Privacy
Henlius respects your privacy. Please refer to our Privacy Notice for details.
Governing Law
These Terms of Use shall be governed by the laws of the People’s Republic of China.
Last updated: March 30, 2026